Literature DB >> 31868271

A prospective evaluation of health-related quality of life after skull base re-irradiation.

Houda Bahig1, Sweet P Ng1, Courtney Pollard1, Theresa P Nguyen1, Gary B Gunn1, David I Rosenthal1, Clifton D Fuller1, Steven J Frank1, Adam S Garden1, Jay P Reddy1, William H Morrison1, Renata Ferrarotto2, Ehab Y Hanna3, Franco DeMonte4, Shirley Y Su3, Jack Phan1.   

Abstract

PURPOSE: To report cancer control outcomes and health-related quality of life (HRQoL) outcomes after highly conformal skull-based re-irradiation (re-RT).
METHODS: Patients planned for curative intent re-RT to a recurrent or new skull base tumor were enrolled. HRQoL were assessed using the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) and the anterior skull base surgery quality of life (ASBQ) questionnaires.
RESULTS: Thirty-nine patients were treated with stereotactic body RT or intensity modulated RT. Median follow-up was 14 months. Progression free survival was 71% at 1-year. There was mild clinically significant worsening of fatigue, lack of appetite and drowsiness (MDASI-BT), and physical function (ASBQ) at the end of RT, followed by recovery to baseline on subsequent follow-ups. Subjective emotions were clinically improved at 12 months, with patients reporting feeling less tense/nervous.
CONCLUSION: Conformal skull base re-RT is associated with mild immediate deterioration in physical function followed by rapid and sustained recovery.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  health-related quality of life; intensity modulation; patient-reported outcomes; quality of life; re-irradiation; skull base tumor; stereotactic body radiotherapy

Mesh:

Year:  2019        PMID: 31868271     DOI: 10.1002/hed.26037

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  Functional Outcomes and Quality of Life in Patients with Sinonasal, Nasopharyngeal, and Anterior Skull Base Tumors.

Authors:  Yelda Jozaghi; Jack Phan; Ehab Y Hanna; Michael E Kupferman; Shirley Y Su
Journal:  Curr Oncol Rep       Date:  2022-03-15       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.